Cevipabulin fumarate

Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [3H]NSC 49842 to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].

Product Specifications

CAS Number

[849550-67-0]

Product Name Alternative

TTI-237 fumarate

UNSPSC

12352005

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Cevipabulin_fumarate.html

Concentration

10mM

Purity

99.87

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 1.43 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[C@@H](C(F)(F)F)NC1=C(C2=C(F)C=C(OCCCNC)C=C2F)C(Cl)=NC3=NC=NN13.O=C(O)/C=C/C(O)=O

Molecular Formula

C22H22ClF5N6O5

Molecular Weight

580.89

References & Citations

[1]Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68 (7) :2292-300.|[2]Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both DB01229-like and Leurocristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64 (4) :681-9.